18F-FDG PET in the Assessment of Tumor Grade and Prediction of Tumor Recurrence in Intracranial Meningioma
Overview
Nuclear Medicine
Radiology
Authors
Affiliations
Purpose: The purpose of this study was to investigate the role of (18)F-fluorodeoxyglucose (FDG) PET in detecting high-grade meningioma and predicting the recurrence in patients with meningioma after surgical resection.
Methods: Fifty-nine patients (27 men and 32 women) with intracranial meningioma who underwent preoperative FDG PET and subsequent surgical resection were enrolled. All patients underwent clinical follow-up for tumor recurrence with a mean duration of 34+/-20 months. The tumor to gray matter ratio (TGR) of FDG uptake was calculated and a receiver-operating characteristic (ROC) curve of the TGR was drawn to determine the cutoff value of the TGR for detection of high-grade meningioma. Further, univariate analysis with the log-rank test was performed to assess the predictive factors of meningioma recurrence.
Results: The TGR in high-grade meningioma (WHO grade II and III) was significantly higher than that in low-grade ones (WHO grade I) (p=0.002) and significantly correlated with the MIB-1 labeling index (r=0.338, p=0.009) and mitotic count of the tumor (r=0.284, p=0.03). The ROC analysis revealed that the TGR of 1.0 was the best cutoff value for detecting high-grade meningioma with a sensitivity of 43%, specificity of 95%, and accuracy of 81%. Of 59 patients, 5 (9%) had a recurrent event. In the log-rank test, the TGR, MIB-1 labeling index, presence of brain invasion, and WHO grade were significantly associated with tumor recurrence. The cumulative recurrence-free survival rate of patients with a TGR of 1.0 or less was significantly higher than that of patients with a TGR of more than 1.0 (p=0.0003)
Conclusion: FDG uptake in meningioma was the significant predictive factor of tumor recurrence and significantly correlated with the proliferative potential of the tumor.
Soni N, Ora M, Bathla G, Szekeres D, Desai A, Pillai J AJNR Am J Neuroradiol. 2024; 46(2):240-250.
PMID: 38844366 PMC: 11878982. DOI: 10.3174/ajnr.A8368.
Imaging Characteristics of Meningiomas.
Galldiks N, Hattingen E, Langen K, Tonn J Adv Exp Med Biol. 2023; 1416:21-33.
PMID: 37432617 DOI: 10.1007/978-3-031-29750-2_3.
Advances in PET imaging for meningioma patients.
Galldiks N, Albert N, Wollring M, Werner J, Lohmann P, Villanueva-Meyer J Neurooncol Adv. 2023; 5(Suppl 1):i84-i93.
PMID: 37287577 PMC: 10243856. DOI: 10.1093/noajnl/vdac113.
Meningioma grading based on positron emission tomography: A systematic review and meta-analysis.
Filis P, Alexiou G, Zigouris A, Sioka C, Filis N, Voulgaris S World Neurosurg X. 2023; 18:100167.
PMID: 36825220 PMC: 9941365. DOI: 10.1016/j.wnsx.2023.100167.
Clinical Management of Supratentorial Non-Skull Base Meningiomas.
Adekanmbi A, Youngblood M, Karras C, Oyetunji E, Kalapurakal J, Horbinski C Cancers (Basel). 2022; 14(23).
PMID: 36497370 PMC: 9737260. DOI: 10.3390/cancers14235887.